Zobrazeno 1 - 10
of 23
pro vyhledávání: ''
Autor:
Engin Ozcivici, Melis Olcum
Publikováno v:
Cancer Cell International
Ozcivici, Engin/0000-0003-4464-0475
PubMed: 25349533
Introduction: Mechanical loads can regulate cell proliferation and differentiation at various stages of development and homeostasis. However, the extension of this regulatory effect of me
PubMed: 25349533
Introduction: Mechanical loads can regulate cell proliferation and differentiation at various stages of development and homeostasis. However, the extension of this regulatory effect of me
Autor:
Aleida Olivares, Patricia Casas-González, Marco Allán Pérez-Solis, Arturo Aguilar-Rojas, Guadalupe Maya-Núñez
Publikováno v:
Cancer Cell International
Through research carried out in the last 25 years about the breast cancer etiology, it has been possible to estimate that less than 10 % of patients who are diagnosed with the condition are carriers of some germline or somatic mutation. The clinical
Publikováno v:
Cancer Cell International
Background Autophagy can either be protective and confer survival to stressed cells, or it can contribute to cell death. The antimitotic drug 2-ethyl-3-O-sulpamoyl-estra-1,3,5(10),15-tetraen-17-ol (ESE-15-ol) is an in silico-designed 17-β-estradiol
Autor:
Hossein Ghasemzadeh Kolagar, Soheila Yadollah-Damavandi, Mohammad Amin Azizi, Mohammad Amin Javidi, Tina Parsa, Ehsan Jangholi, Yekta Parsa, Seyed Abbas Mirmalek, Reza Alizadeh-Navaei, Seyed Alireza Salimi-Tabatabaee
Publikováno v:
Cancer Cell International
Background Breast cancer is the most prevalent malignancies among the women that have a high mortality. Previous studies demonstrated that hypericin, a bioactive component of Hypericum perforatum have a cytotoxic effect on the malignant cell lines. H
Publikováno v:
Cancer Cell International
Background Suberoyl bis-hydroxamic acid (SBHA) is a histone deacetylase (HDAC) inhibitor and exerts anti-growth effects in several malignancies including breast cancer. Proteasome inhibitors such as Bortezomib and MG-132 constitute novel anticancer a
Autor:
Jiong Wu, Mengying Liu, Shuling Zhou, Yayun Chi, Lin Yuan, Bingqing Zhou, Naisi Huang, Sheng Huang
Publikováno v:
Cancer Cell International
Background Accumulating studies have focused on the oncogenic and tumor suppressive roles of the newly identified lncRNAs. A novel lncRNA BC040587 in 3q13.31 locus which exists frequent copy number alterations was found to be associated with poor sur
Autor:
Liu-Mei Shou, Meng Shen, Kai Chen, Meng-Dan Xu, Min Jiang, Meng-Yao Wu, Wei-Ming Duan, Xiao Wu, Wei Li, Juan Hou, Min Tao, Fei-Ran Gong, Xiaojie Bian, Qiaoming Zhi
Publikováno v:
Cancer Cell International
Purpose Despite new developments in cancer therapy, chemotherapy and radiotherapy remain the cornerstone of breast cancer treatment. Therefore, finding ways to reduce the toxicity and increase sensitivity is particularly important. Tumor necrosis fac
Autor:
Elizabeth C. Punska, Brian T. Pentecost, Kathleen F. Arcaro, Kevin D. Christie, Eva P. Browne, Christopher N. Otis, Leo O. Simmons, Rahul M. Jawale, Kristin E. Williams, Lily M. Fitzgerald
Publikováno v:
Cancer Cell International
Background Most women with primary breast cancers that express estrogen receptor alpha (ER or ESR1) are treated with endocrine therapies including the anti-estrogen tamoxifen, but resistance to these anti-endocrine therapies often develops. This stud
Autor:
Xiao-Xu Liu, Meng Wang, Weili Min, Zhijun Dai, Huafeng Kang, Yong-Ping Shao, Xi-Jing Wang, Shuai Lin, Hong-Tao Ren, Yang Zhao
Publikováno v:
Cancer Cell International
Background Published data on the association between AURKA polymorphisms and breast cancer (BC) risk are inconclusive. This meta-analysis was performed to derive a more precise estimation on the relationship between AURKA polymorphisms (rs2273535 and
Autor:
Guan Liu, Dehong Zou, Xiangming He, Xuebing Yan, Xiangyun Zong, Hongjian Yang, Hua Xiang, Yang Yu
Publikováno v:
Cancer Cell International
Background Cell cycle regulatory pathway is a well-established pathway mainly dependent on cyclin-dependent kinases (CDKs), which are regulated positively by cyclins and negatively by cyclin-dependent kinase inhibitors(CKIs). Cyclin-dependent kinase